Show simple item record

dc.contributor.authorSharma, RA
dc.contributor.authorPlummer, R
dc.contributor.authorStock, JK
dc.contributor.authorGreenhalgh, TA
dc.contributor.authorAtaman, O
dc.contributor.authorKelly, S
dc.contributor.authorClay, R
dc.contributor.authorAdams, RA
dc.contributor.authorBaird, RD
dc.contributor.authorBillingham, L
dc.contributor.authorBrown, SR
dc.contributor.authorBuckland, S
dc.contributor.authorBulbeck, H
dc.contributor.authorChalmers, AJ
dc.contributor.authorClack, G
dc.contributor.authorCranston, AN
dc.contributor.authorDamstrup, L
dc.contributor.authorFerraldeschi, R
dc.contributor.authorForster, MD
dc.contributor.authorGolec, J
dc.contributor.authorHagan, RM
dc.contributor.authorHall, E
dc.contributor.authorHanauske, A-R
dc.contributor.authorHarrington, KJ
dc.contributor.authorHaswell, T
dc.contributor.authorHawkins, MA
dc.contributor.authorIllidge, T
dc.contributor.authorJones, H
dc.contributor.authorKennedy, AS
dc.contributor.authorMcDonald, F
dc.contributor.authorMelcher, T
dc.contributor.authorO'Connor, JPB
dc.contributor.authorPollard, JR
dc.contributor.authorSaunders, MP
dc.contributor.authorSebag-Montefiore, D
dc.contributor.authorSmitt, M
dc.contributor.authorStaffurth, J
dc.contributor.authorStratford, IJ
dc.contributor.authorWedge, SR
dc.contributor.authorNCRI CTRad Academia-Pharma Joint Working Group
dc.date.accessioned2016-08-26T15:13:03Z
dc.date.issued2016-10
dc.identifier.citationNature reviews. Clinical oncology, 2016, 13 (10), pp. 627 - 642
dc.identifier.issn1759-4774
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/74
dc.identifier.eissn1759-4782
dc.identifier.doi10.1038/nrclinonc.2016.79
dc.description.abstractIn countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a single modality or combined with other treatments. Radiotherapy can provide enormous benefit to patients with cancer. In the past decade, significant technical advances, such as image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with significantly lower doses to normal surrounding tissues. However, apart from the combination of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in identifying and defining optimal targeted therapy and radiotherapy combinations to improve the efficacy of cancer treatment. The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group with representatives from academia, industry, patient groups and regulatory bodies to address this lack of progress and to publish recommendations for future clinical research. Herein, we highlight the Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer.
dc.formatPrint-Electronic
dc.format.extent627 - 642
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectNCRI CTRad Academia-Pharma Joint Working Group
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectTreatment Outcome
dc.subjectCombined Modality Therapy
dc.subjectDrug Approval
dc.subjectRadiation Dosage
dc.subjectCell Hypoxia
dc.subjectRadiation Tolerance
dc.subjectPatient Participation
dc.subjectQuality of Health Care
dc.subjectQuality Assurance, Health Care
dc.subjectClinical Trials as Topic
dc.subjectPatient Education as Topic
dc.titleClinical development of new drug-radiotherapy combinations.
dc.typeJournal Article
dcterms.dateAccepted2016-05-15
rioxxterms.versionofrecord10.1038/nrclinonc.2016.79
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature reviews. Clinical oncology
pubs.issue10
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsNo embargo
icr.researchteamICR-CTSU Urology and Head and Neck Trials Teamen_US
icr.researchteamQuantitative Biomedical Imagingen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHall, Emmaen
dc.contributor.icrauthorHarrington, Kevinen
dc.contributor.icrauthorO'Connor, James Patricken


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0